Activating telomerase TERT promoter mutations and their application for the detection of bladder cancer

Zvereva, M.; Pisarev, E.; Hosen, I.; Kisil, O.; Matskeplishvili, S.; Kubareva, E.; Kamalov, D.; Tivtikyan, A.; Manel, A.; Vian, E.; Kamalov, A.; Kamalov, A.; Ecke, T.; Calvez-Kelm, F.L.

Статья опубликована в высокорейтинговом журнале

Информация о цитировании статьи получена из Scopus, Web of Science
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 ноября 2020 г.

Авторы: Zvereva M., Pisarev E., Hosen I., Kisil O., Matskeplishvili S., Kubareva E., Kamalov D., Tivtikyan A., Manel A., Vian E., Kamalov A., Kamalov A., Ecke T., Calvez-Kelm F.L.
Журнал: International Journal of Molecular Sciences
Том: 21
Номер: 17
Год издания: 2020
Издательство: MDPI
Местоположение издательства: Basel, Switzerland
Первая страница: 6034
Последняя страница: 6052
DOI: 10.3390/ijms21176034
Аннотация: This review summarizes state-of-the-art knowledge in early-generation and novel urine biomarkers targeting the telomerase pathway for the detection and follow-up of bladder cancer (BC). The limitations of the assays detecting telomerase reactivation are discussed and the potential of transcription-activating mutations in the promoter of the TERT gene detected in the urine as promising simple non-invasive BC biomarkers is highlighted. Studies have shown good sensitivity and specificity of the urinary TERT promoter mutations in case-control studies and, more recently, in a pilot prospective cohort study, where the marker was detected up to 10 years prior to clinical diagnosis. However, large prospective cohort studies and intervention studies are required to fully validate their robustness and assess their clinical utility. Furthermore, it may be interesting to evaluate whether the clinical performance of urinary TERT promoter mutations could increase when combined with other simple urinary biomarkers. Finally, different approaches for assessment of TERT promoter mutations in urine samples are presented together with technical challenges, thus highlighting the need of careful technological validation and standardization of laboratory methods prior to translation into clinical practice.Keywords: TERT promoter region; biomarkers; bladder cancer; non-invasive detection; somatic mutations; telomerase.
Добавил в систему: Тивтикян Александр Сергеевич

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

Activating telomerase TERT promoter mutations and their application for the detection of bladder cancerстатья Исследовательская статья

Прикрепленные файлы